# Zevra Therapeutics share price today (Zevra Therapeutics, Inc., ZVRA)

> Zevra Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ZVRA · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/zvra

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $11.17 (+26.8% in a year)
- P/E: 9.1×, over 1 year
- Revenue (Jun 2026): $39.7 M (+53.3% on a year ago)
- Profit (Jun 2026): $8.4 M (−87.6% on a year ago)
- Operating margin: 42.3% (+89.9 points on a year ago)
- ROE: 50%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Zevra Therapeutics share price today? Zevra Therapeutics, Inc.'s share price was $11.17 at the close on 4 November 2026. That is 3.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $14, and at that close it sat 50% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 1 year the share price moved −11% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Zevra Therapeutics pay? Zevra Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Zevra Therapeutics on? Zevra Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Zevra Therapeutics profitable? Zevra Therapeutics, Inc. earned $8.4 M of net profit in the Jun 2026 quarter, −87.6% on the same quarter a year earlier. Full-year FY25 profit was $77.6 M. That is 21.2% of the quarter's revenue. The same quarter a year earlier earned $67.9 M. 8 of the last 12 reported quarters were loss-making. ## How much revenue does Zevra Therapeutics make, and is it growing? Zevra Therapeutics, Inc. reported $39.7 M of revenue in the Jun 2026 quarter, +53.3% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 38.8% a year on average. The last full year, FY25, came in at $106 M. The last four reported quarters add to $136 M. FY25 revenue was $106 M, +350.9% on the year before. Recent pace: the last four quarters grew +229.9% on average, against 38.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +119.4%, against +139.7% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Zevra Therapeutics keep? Zevra Therapeutics, Inc.'s operating margin was 42.3% in the Jun 2026 quarter, 89.9 percentage points higher than the same quarter a year ago. Across 5 years it has been between −368.5% and 27.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +89.9 percentage points on the year while gross margin changed +44.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Zevra Therapeutics' profit turning into cash? Zevra Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $1.6 M of cash, against $77.6 M of profit. After $835 K of spending on assets, free cash was −$2.4 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Zevra Therapeutics' cash go? Zevra Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 M on assets over the last 3 years. Averaged over those years that is 0.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.2 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Zevra Therapeutics' P/E ratio, and how does it compare with its own history? Zevra Therapeutics, Inc.'s P/E is 9.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Zevra Therapeutics business getting better or worse? Zevra Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Zevra Therapeutics earn on its capital? Zevra Therapeutics, Inc. earned a ROE of 50% in FY25. That is up from a low of −266% in FY24. Its return on capital used (ROIC) is 80.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 72.9% net margin and 0.37× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 72.9% net margin × 0.37× asset turnover × 1.84× leverage (assets divided by equity) ≈ 49.6% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 90.4% − 10.1% = +80.3 percentage points. The 10.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 90.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −14.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Zevra Therapeutics have too much debt? Zevra Therapeutics, Inc. has total debt of $1.5 M against shareholder equity of $218 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.41 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Zevra Therapeutics shareholding pattern? 11.6% of Zevra Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Zevra Therapeutics from balance-sheet trouble? For Zevra Therapeutics, Inc., the Z-score is 4.91. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.91 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Zevra Therapeutics rank in its industry? There is no score against its industry: Zevra Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Zevra Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Zevra Therapeutics in size? Zevra Therapeutics is the 130th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Candel Therapeutics, Inc., 4D Molecular Therapeutics, Inc. and Kura Oncology, Inc. Just below it: Lexicon Pharmaceuticals, Inc., SL Science Holding and DBV Technologies S.A. ### Biotechnology companies close in size

1. [Candel Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cadl) $692 million
2. [4D Molecular Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fdmt) $678 million
3. [Kura Oncology, Inc.](https://www.sectoralpha.in/us/stocks/kura) $677 million
4. Zevra Therapeutics, Inc. $665 million
5. [Lexicon Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/lxrx) $659 million
6. [SL Science Holding Limited](https://www.sectoralpha.in/us/stocks/slbt) $633 million
7. [DBV Technologies S.A.](https://www.sectoralpha.in/us/stocks/dbvt) $622 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [MFA Financial, Inc.](https://www.sectoralpha.in/us/stocks/mfa) $668 million · REIT - Mortgage
2. [Mativ Holdings, Inc.](https://www.sectoralpha.in/us/stocks/matv) $668 million · Specialty Chemicals
3. Zevra Therapeutics, Inc. $665 million
4. [Tron Inc.](https://www.sectoralpha.in/us/stocks/tron) $664 million · Leisure
5. [Lightwave Logic, Inc.](https://www.sectoralpha.in/us/stocks/lwlg) $663 million · Specialty Chemicals

## What else do people ask about Zevra Therapeutics? ### What were Zevra Therapeutics's latest quarterly results? Zevra Therapeutics, Inc. reported revenue of $39.7 M and net profit of $8.4 M for the Jun 2026 quarter. Revenue rose 53.3% and profit fell 87.6% compared with a year earlier. Earnings per share were $0.14. The operating margin was 42.3%, 89.9 percentage points higher than a year earlier (as of 4 November 2026). ### What is Zevra Therapeutics's market cap? Zevra Therapeutics, Inc.'s market capitalisation is $665 M at a stock price of $11.17. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Zevra Therapeutics performing? Zevra Therapeutics, Inc.'s latest readings are below. In its latest quarter, revenue rose 53.3% and profit fell 87.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Zevra Therapeutics's stock price go up? This page does not forecast Zevra Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $11.17. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Zevra Therapeutics in its business cycle? Zevra Therapeutics, Inc.'s FY25 operating margin was −4.0%, against a 5-year range of −368.5% to 27.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 42.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Zevra Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Zevra Therapeutics a stock worth studying right now? What the numbers show: Zevra Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.